Search results
Results: 88
Number of items: 88
-
Koers, J., Pollastro, S., Tol, S., Pico-Knijnenburg, I., Derksen, N. I. L., van Schouwenburg, P. A., van der Burg, M., van Ham, S. M., & Rispens, T. (2022). CD45RB Glycosylation and Ig Isotype Define Maturation of Functionally Distinct B Cell Subsets in Human Peripheral Blood. Frontiers in Immunology, 13, Article 891316. https://doi.org/10.3389/fimmu.2022.891316 -
Koers, J., Marsman, C., Steuten, J., Tol, S., Derksen, N. I. L., ten Brinke, A., van Ham, S., & Rispens, T. (2022). Oxygen level is a critical regulator of human B cell differentiation and IgG class switch recombination. Frontiers in Immunology, 13, Article 1082154. https://doi.org/10.3389/fimmu.2022.1082154
-
van Kempen, Z. L. E., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Dam, P. J., Volkers, A. G., Boekel, L., Toorop, A. A., Strijbis, E. M. M., Tas, S. W., Wolbink, G. J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N. J. M., Steenhuis, M., Kuijpers, T. W., van Ham, S. M., Rispens, T., ... T2B! immunity against SARS-CoV-2 study group (2022). Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? Multiple sclerosis and related disorders, 57, Article 103416. https://doi.org/10.1016/j.msard.2021.103416
-
Marsman, C., Verhoeven, D., Koers, J., Rispens, T., ten Brinke, A., van Ham, S. M., Kuijpers, T. W., & T2B Consortium (2022). Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells. Frontiers in Immunology, 13, Article 815449. https://doi.org/10.3389/fimmu.2022.815449
-
Wieske, L., Takkenberg, R. B., Tas, S. W., Bemelman, F. J., ten Brinke, A., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 20, Article 100. https://doi.org/10.1186/s12916-022-02310-7
-
van Dam, K. P. J., Hogenboom, L., Stalman, E. W., Kummer, L. Y. L., Steenhuis, M., Keijser, J. B. D., ten Brinke, A., van Ham, S. M., Kuijpers, T. W., Rispens, T., Wieske, L., Eftimov, F., Strijbis, E. M., Killestein, J., van Kempen, Z. L. E., & T2B! immunity against SARS-CoV-2 study group (2022). Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination. Frontiers in Neurology, 13, Article 1032830. https://doi.org/10.3389/fneur.2022.1032830
-
Verstegen, N. J. M., Hagen, R. R., van den Dijssel, J., Kuijper, L. H., Kreher, C., Ashhurst, T., Kummer, L. Y. L., Steenhuis, M., Duurland, M., de Jongh, R., de Jong, N., van der Schoot, C. E., Bos, A. V., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Wolbink, G., ... T2B! immunity against SARS-CoV-2 study group (2022). Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. eLife, 11, Article e77969. https://doi.org/10.7554/eLife.77969
-
Palomares Cabeza, V., Kummer, L. Y. L., Wieske, L., Hagen, R. R., Duurland, M., Konijn, V. A. L., van Dam, K. P. J., Stalman, E. W., van de Sandt, C. E., Boekel, L., Verstegen, N. J. M., Steenhuis, M., Rispens, T., Tas, S. W., Wolbink, G., Killestein, J., Kuijpers, T. W., van Ham, S. M., Eftimov, F., ... Target-to-B! (T2B!) SARS-CoV-2 study group (2022). Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. Neurology® Neuroimmunology & Neuroinflammation, 9(4), Article e1178. https://doi.org/10.1212/NXI.0000000000001178
-
Bos, A. V., van Gool, M. M. J., Breedveld, A. C., van der Mast, R., Marsman, C., Bouma, G., van de Wiel, M. A., van Ham, S. M., Mebius, R. E., & van Egmond, M. (2022). Fcα Receptor-1-Activated Monocytes Promote B Lymphocyte Migration and IgA Isotype Switching. International Journal of Molecular Sciences, 23(19), Article 11132. https://doi.org/10.3390/ijms231911132
Page 5 of 9